Author(s)

Shengxuan Chi, Liwei Guo, Yuting Shi

Corresponding Author

Shengxuan Chi

ABSTRACT

The PI3K signaling pathway is one of the important signal transduction pathways in cells, and it is also a common abnormal expression signal pathway in cancer cells. Cell proliferation, differentiation, death, glucose transport, and other cell processes are all regulated by the PI3K signaling system. Because of this, both the occurrence and development of a range of tumors are thought to be inextricably linked to PI3K. In recent years, the study of anti-tumor regulatory mechanisms with PI3K as a molecular target has attracted much attention. According to the different regulatory mechanisms of the PI3K signaling pathway, Pan-PI3K Inhibitors, Dual PI3K/mTOR Inhibitors, and Isoform-specific PI3K Inhibitors are the three types of inhibitors. At present, many studies have found a variety of effective inhibitors, and these inhibitors provide more directions and options for the treatment of various tumors. Research on PI3K inhibitors is ongoing. This article reviews the research progress of PI3K pathway inhibitors in anti-tumor aspects in recent years.

KEYWORDS

Cancer, PI3K pathway, PI3K inhibitors, Targeted therapy